Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nancy E Davidson

Showing results (131-140 of 285) with videos related to

Pageof 29
Sort By:
Cancer Biology & Therapy|January 22, 2005
Epigenetic regulation of protein phosphatase 2A (PP2A), lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cellsJudith C Keen, Elizabeth Garrett-Mayer, Catherine Pettit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2008
A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancerCarlos L Arteaga, Anne O'Neill, Stacy L Moulder, et al.
Plos One|October 3, 2013
Integrated proteomic and metabolic analysis of breast cancer progressionPatrick G Shaw, Raghothama Chaerkady, Tao Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 6, 2008
Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197Lori J Goldstein, Anne O'Neill, Joseph A Sparano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2005
Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188)Nancy E Davidson, Anne M O'Neill, Allen M Vukov, et al.
International Journal of Cancer|April 11, 2018
HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cellsChunyu Cao, Hao Wu, Shauna N Vasilatos, et al.
The Journal of Biological Chemistry|June 21, 2005
Protein phosphatase 2A regulates estrogen receptor alpha (ER) expression through modulation of ER mRNA stabilityJudith C Keen, Qun Zhou, Ben Ho Park, et al.
Cancer Biology & Therapy|September 1, 2005
Role of p53/p21(Waf1/Cip1) in the regulation of polyamine analogue-induced growth inhibition and cell death in human breast cancer cellsYi Huang, Allison Pledgie, Ethel Rubin, et al.
The New England Journal of Medicine|December 28, 2007
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancerKathy Miller, Molin Wang, Julie Gralow, et al.
Cancer Chemotherapy and Pharmacology|September 4, 2009
The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell linesAllison Pledgie-Tracy, Madhavi Billam, Amy Hacker, et al.
Pageof 29

Showing results (131-140 of 285) with videos related to

Sort By:
Pageof 29
Cancer Biology & Therapy|January 22, 2005
Epigenetic regulation of protein phosphatase 2A (PP2A), lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cellsJudith C Keen, Elizabeth Garrett-Mayer, Catherine Pettit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2008
A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancerCarlos L Arteaga, Anne O'Neill, Stacy L Moulder, et al.
Plos One|October 3, 2013
Integrated proteomic and metabolic analysis of breast cancer progressionPatrick G Shaw, Raghothama Chaerkady, Tao Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 6, 2008
Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197Lori J Goldstein, Anne O'Neill, Joseph A Sparano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2005
Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188)Nancy E Davidson, Anne M O'Neill, Allen M Vukov, et al.
International Journal of Cancer|April 11, 2018
HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cellsChunyu Cao, Hao Wu, Shauna N Vasilatos, et al.
The Journal of Biological Chemistry|June 21, 2005
Protein phosphatase 2A regulates estrogen receptor alpha (ER) expression through modulation of ER mRNA stabilityJudith C Keen, Qun Zhou, Ben Ho Park, et al.
Cancer Biology & Therapy|September 1, 2005
Role of p53/p21(Waf1/Cip1) in the regulation of polyamine analogue-induced growth inhibition and cell death in human breast cancer cellsYi Huang, Allison Pledgie, Ethel Rubin, et al.
The New England Journal of Medicine|December 28, 2007
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancerKathy Miller, Molin Wang, Julie Gralow, et al.
Cancer Chemotherapy and Pharmacology|September 4, 2009
The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell linesAllison Pledgie-Tracy, Madhavi Billam, Amy Hacker, et al.
Pageof 29